Actuate Therapeutics, Inc. ACTU 深 沪
等待开盘 08-21 09:30:00 美东时间
1.21
+0.150
+14.15%
华盛通- 最 高1.3393
- 今 开1.06
- 成交量 45.63万股
- 最 低 1.0101
- 昨 收 1.06
- 总市值 2905.72万
- 52周最高 9.22
- 市盈率 静 --
- 换手率 1.90%
- 52周最低 0.90
- 委 比 81.40%
- 总股本 2401.42万
- 历史最高 11.99
- 量 比 7.00
- 振 幅 31.06%
- 历史最低 0.90
- 每 手 1
- 风险率 2.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
08-18 18:38
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Actuate Therapeutics (NASDAQ:ACTU) with a Buy rating and announces Price Target of $6.
07-30 20:21
Actuate Therapeutics' Elraglusib To Be Evaluated In BEACON2 Clinical Study To Identify, Proceed To Treat Children With Relapsed, Refractory Neuroblastoma
Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced that elraglusib will be evaluated in the BEACON2
06-09 19:48
Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone- Patients with P53WT genomics
06-01 19:07
Actuate Therapeutics Announces FDA Clearance Of IND For Phase 1/2 Study Of Oral Elraglusib In Advanced Cancer Patients, With Focus On Metastatic Melanoma, NSCLC, Colorectal, And Pancreatic Cancers With Initiation Planned For 2H 2026
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma,
05-11 19:08
美股大行评级 | 巴克莱大幅上调希捷科技、西部数据目标价！联合健康、霍顿房屋、盈透证券、奎斯特诊疗等获多家机构上调目标价
今日重点评级关注：Piper Sandler：维持MeiraGTx Holdings"超配"评级，目标价从26美元升至30美元；康托·菲茨杰拉德：维持MKS Inc."超配"评级，目标价从300美元升至400美元
04-23 12:35
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
04-22 19:59
Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?
Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data showing elraglusib plus chemotherapy improved overall survival in metastatic pancreatic cancer.
04-16 15:34
